Menerba is a first-in-class treatment for hot-flashes experienced during menopause. Prediqtus is the exclusive broker of patent assets for this non-hormonal pharmaceutical composition.
In Phase I and II clinical trials, patients taking Menerba were 2.3 times more likely to have a 50% reduction in the number of hot flashes experienced, with no severe adverse effects compared to those receiving the placebo. The safety and tolerability profile was found to be favorable and superior to existing hormone replacement therapies. The Chemistry, Manufacturing and Controls review has been approved by the U.S. Food and Drug Administration, as required to begin Phase III clinical trials. The compound has strong intellectual property protection, with 38 patents covering the composition of matter, structure-function, and therapeutic use. These patents provide intellectual property protection through 2026.
This represents a unique opportunity for large and small bio-medical research and development companies. For further information, see the Menerba profile on our website: